Article Text

Download PDFPDF

Clinical Trials in Recurrent Ovarian Cancer
  1. Michael Friedlander, MD, PhD*,
  2. Edward Trimble, MD,
  3. Anna Tinker, MD,
  4. David Alberts, MD§,
  5. Elisabeth Avall-Lundqvist, MD, PhD,
  6. Mark Brady, PhD,
  7. Philipp Harter, MD#,
  8. Sandro Pignata, MD, PhD**,
  9. Eric Pujade- Lauraine, MD, PhD,,
  10. Jalid Sehouli, MD#,
  11. Ignace Vergote, MD, PhD,,
  12. Philip Beale, MD*,
  13. Rudd Bekkers, MD§§,
  14. Paula Calvert, MD∥∥,
  15. Lawrence Copeland, MD§,
  16. Ros Glasspool, MD¶¶,
  17. Antonio Gonzalez-Martin, MD##,
  18. Dionysis Katsaros, MD***,
  19. Jae Won Kim, MD†††,
  20. Brigitte Miller, MD‡‡‡,
  21. Diane Provencher, MD,
  22. Lawrence Rubinstein, MD,
  23. Mostafa Atri, MD§,§§,
  24. Alain Zeimet, MD∥∥∥,
  25. Monica Bacon, RN¶¶¶,
  26. Henry Kitchener, MD### and
  27. Gavin C.E. Stuart, MD, FRCSC
  1. * ANZGOG, Australia-New Zealand;
  2. National Cancer Institute;
  3. NCIC-CTG, Canada;
  4. § SWOG;
  5. NSGO, Scandinavia;
  6. GOG;
  7. # AGO OVAR, Germany;
  8. ** MITO, Italy;
  9. †† GINECO, France;
  10. ‡‡ EORTC-GCG, Europe;
  11. §§ DGOG, The Netherlands;
  12. ∥∥ ICORG, Ireland;
  13. ¶¶ SGCTG, Scotland;
  14. ## GEICO, Spain;
  15. *** MANGO, Italy;
  16. ††† KGOG, Korea;
  17. ‡‡‡ RTOG;
  18. §§§ ACRIN;
  19. ∥∥∥ AGO-Au, Austria;
  20. ¶¶¶ Gynecologic Cancer InterGroup; and
  21. ### MRC/NCRI, UK.
  1. Address correspondence and reprint requests to Michael Friedlander, MD, PhD, Department of Medical Oncology, The Prince of Wales Cancer Centre, Randwick, NSW, Australia. E-mail: michael.friedlander{at}


The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

  • Ovarian cancer
  • Recurrent
  • Clinical trials

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.